ESTRO 2024 - Abstract Book

S921

Clinical - CNS

ESTRO 2024

UK CCLG recommendations were closely followed in the UK. Since autumn 2022, for localised bifocal germinoma, we have also omitted the boost to primary sites in complete radiological response post chemotherapy (5).

In this study, we assessed oncologic outcomes for a contemporary cohort of patients treated with proton therapy at our centre.

Material/Methods:

A retrospective review of prospectively collected data. All patients referred for proton therapy to our centre from December 2018 have been included. One previously irradiated patient referred for re-irradiation has been excluded. Baseline patient, tumour and treatment factors were collected, as were severe acute toxicities (CTCAE grade ≥ 3), and progression and survival outcomes. Patients were followed up until 12/09/2023. Follow up and progression were calculated from the end date of radiotherapy.

Results:

Sixty-six patients were included, with median follow up 14.14 months (IQR 6.67-25.71). Baseline and treatment characteristics are shown in Table 1.